Suresh Ambudkar

Assistant Professor

Johns Hopkins University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Suresh Ambudkar is an Assistant Professor at the Johns Hopkins School of Medicine in the United States. His research primarily focuses on the mechanisms of drug resistance in cancer, particularly involving ABC transporters such as P-glycoprotein and ABCG2. Recent publications include studies on overcoming drug efflux in chemoresistant cancer cells and the structural characterization of drug transport mechanisms.

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (7)

Zhe-Sheng Chen

Professor

St. John's University

UNITED STATES

View details

Ahcène Boumendjel

Full Professor

Université Grenoble Alpes

FRANCE

View details

Susana P. Cunha

University of Coimbra

PORTUGAL

View details

Hugo Filipe

Instituto Politécnico da Guarda

PORTUGAL

View details

Thales Kronenberger

GERMANY

View details

Luís M. S. Loura

University of Coimbra

PORTUGAL

View details

Antti Poso

Professor at University of Eastern Finland

University of Eastern Finland

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Suresh Ambudkar

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Photodynamic priming modulates cellular ATP levels to overcome P‐glycoprotein‐mediated drug efflux in chemoresistant triple‐negative breast cancer

Mutational analysis reveals the importance of residues of the access tunnel inhibitor site to human P‐glycoprotein (ABCB1)‐mediated transport

ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells

Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2

Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery

Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells

Residues from Homologous Transmembrane Helices 4 and 10 Are Critical for P-Glycoprotein (ABCB1)-Mediated Drug Transport

Correction to “BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistance in Vitro and in Vivo”

ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines

Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability

Interaction of a Homologous Series of Amphiphiles with P-glycoprotein in a Membrane Environment—Contributions of Polar and Non-Polar Interactions

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport

Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells

Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer

Collaborators (7)

Zhe-Sheng Chen

Ahcène Boumendjel

Susana P. Cunha

Hugo Filipe

Thales Kronenberger

Luís M. S. Loura

Antti Poso

Make your next move.